Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06947304 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

A Phase 1 study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), sponsored by Corcept Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06947304 is a Phase 1 study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 8 participants, below the 72-participant average among 6 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06947304, a Phase 1 study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), is actively recruiting participants, sponsored by Corcept Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Interventions

  • DRUG Miricorilant

Study Locations (1)

Missouri

  • University of Missouri - Columbia

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-08-22
Est. Completion 2026-05
Phase Phase 1

Sponsor

Corcept Therapeutics

54 total trials

What the Registry Record Tells You About NCT06947304

The ClinicalTrials.gov registry entry for NCT06947304 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 6 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (89% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Non-Alcoholic Fatty Liver Disease (NAFLD) appearing as the primary indexed condition, and to 1 intervention - of which Miricorilant is the first listed.

NCT06947304 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06947304 about?

NCT06947304 is a clinical study titled "Evaluation of Miricorilant on Liver Fat in Patients With MASLD". A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

What is the current status of trial NCT06947304?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-22. Estimated completion is 2026-05.

What conditions does trial NCT06947304 study?

This clinical trial studies the following conditions: Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

What interventions are being tested in trial NCT06947304?

The interventions under investigation include: Miricorilant (DRUG).

Who is sponsoring clinical trial NCT06947304?

This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06947304 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Alcoholic Fatty Liver Disease (NAFLD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.